Literature DB >> 6549113

Lymphoid tumors of the orbit and ocular adnexa: a long-term follow-up.

K V Vogiatzis.   

Abstract

Retrospective review of 33 patients followed for up to 14 years showed that no signs, symptoms, or histopathologic classification were able to correlate with the long-term fate of the patient. In some cases the histologic pictures were diagnosed differently by different pathologists, pointing up the difficulty encountered in differentiating benign from malignant tumor. Among the interesting clinical findings were: (a) all eight cases of bilateral involvement of the eye or orbital involvement proved to be or developed later systemic lymphomas; (b) one half of the systemic cases (7 out of 15) had ophthalmic involvement from the start; (c) five out of six cases of the medial conjunctival involvement were found to be ultimately malignant. A long-term follow-up and the fate of the patient has to be the final arbiter as to whether the lesion was benign or malignant in a significant number of cases.

Entities:  

Mesh:

Year:  1984        PMID: 6549113

Source DB:  PubMed          Journal:  Ann Ophthalmol        ISSN: 0003-4886


  3 in total

1.  Long term outcome of ocular adnexal lymphoma subtyped according to the REAL classification. Revised European and American Lymphoma.

Authors:  C Auw-Haedrich; S E Coupland; A Kapp; A Schmitt-Gräff; R Buchen; H Witschel
Journal:  Br J Ophthalmol       Date:  2001-01       Impact factor: 4.638

2.  The cytological, immunocytochemical and molecular genetic analysis in diagnosis of the neoplasms of the eye, eye adnexa and orbit.

Authors:  Z Krzystolik; A Rosławska; E Bedner
Journal:  Doc Ophthalmol       Date:  1994       Impact factor: 2.379

3.  Clinical course and pathologic features of conjunctival non-Hodgkin's lymphoma. A report of six cases.

Authors:  H A Khalil; R J de Keizer; P M Kluin; H C Kluin-Nelemans; D de Wolff-Rouendaal
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.